Treatment and management of myelofibrosis in the era of JAK inhibitors

References

• MesaRAGreenABarosiGVerstovsekSVardimanJGaleRPMPN-associated myelofibrosis (MPN-MF)Leuk Res2011351121320684988
   PubMed Web of Science ®Google Scholar
• CervantesFDupriezBPereiraANew prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood2009113132895290118988864
   PubMed Web of Science ®Google Scholar
• BarosiGRostiVVannucchiAMTherapeutic approaches in myelofibrosisExpert Opin Pharmacother201112101597161121457082
   PubMed Web of Science ®Google Scholar
• JamesCUgoVLe CouédicJPA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature200543470371144114815793561
   PubMed Web of Science ®Google Scholar
• KralovicsRPassamontiFBuserASA gain-of-function mutation of JAK2 in myeloproliferative disordersN Engl J Med2005352171779179015858187
   PubMed Web of Science ®Google Scholar
• BaxterEJScottLMCampbellPJAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersLancet200536594641054106115781101
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• ScottLMTongWLevineRLJAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisN Engl J Med2007356545946817267906
   PubMed Web of Science ®Google Scholar
• OhSTSimondsEFJonesCNovel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasmsBlood2010116698899220404132
   PubMed Web of Science ®Google Scholar
• PikmanYLeeBHMercherTMPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaPLoS Med200637e27016834459
   PubMed Web of Science ®Google Scholar
• MesaRANiblackJWadleighMThe burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patientsCancer20071091687617123268
   PubMed Web of Science ®Google Scholar
• PassamontiFCervantesFVannucchiAMDynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosisBlood2010116152857285820947690
   PubMed Web of Science ®Google Scholar
• PassamontiFCervantesFVannucchiAMA dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood201011591703170820008785
   PubMed Web of Science ®Google Scholar
• GangatNCaramazzaDVaidyaRDIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusJ Clin Oncol201129439239721149668
   PubMed Web of Science ®Google Scholar
• VannucchiAMLashoTLGuglielmelliPMutations and prognosis in primary myelofibrosisLeukemia Epub4262013
   Web of Science ®Google Scholar
• Jakafi (ruxolitinib) [package insert]Wilmington, DEIncyte Corporation2011
   Google Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar
• VerstovsekSPassamontiFRambaldiALong-term efficacy and safety results from a phase II study of ruxolitinib in patients with polycythemia veraBlood (ASH Annual Meeting Abstracts)201212021804
   Google Scholar
• CervantesFKiladjianJNiederwieserDLong-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF)Blood (ASH Annual Meeting Abstracts)201212021801
   Web of Science ®Google Scholar
• VerstovsekSMesaRGotlibJLong-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-IBlood (ASH Annual Meeting Abstracts)201212021800
   PubMed Web of Science ®Google Scholar
• KvasnickaHMThieleJBueso-RamosCLong-term intervention effects on bone marrow morphology in myelofibrosis: Patients treated with ruxolitinib and best available therapyHaematologica201398Suppl 1249 [abstract S591]
   Google Scholar
• KvasnickaHMThieleJBueso-RamosCExploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosisJ Clin Oncol, 2013 Annual Meeting Proc (Post-Meeting Edition)201331Suppl 15 (May 20 Suppl)[abstract 7030]
   Google Scholar
• VannucchiAKiladjianJJGisslingerHReductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase 3 study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT)Haematologica201297Suppl 1151 [abstract 0373]21993684
   PubMed Web of Science ®Google Scholar
• WernigGKharasMGOkabeREfficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraCancer Cell200813431132018394554
   PubMed Web of Science ®Google Scholar
• TalpazMJamiesonCGabrailNA phase II randomized doseranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) M FBlood (ASH Annual Meeting Abstracts)2012120212837
   Web of Science ®Google Scholar
• PardananiAGotlibJRJamiesonCSafety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosisJ Clin Oncol201129778979621220608
   PubMed Web of Science ®Google Scholar
• PardananiAGotlibJGuptaVPhase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosisBlood (ASH Annual Meeting Abstracts)201212021178
   Web of Science ®Google Scholar
• KomrokjiRSWadleighMSeymourJFResults of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosisBlood (ASH Annual Meeting Abstracts)201111821282
   Web of Science ®Google Scholar
• McLornanDPMeadAJJacksonGHarrisonCNAllogeneic stem cell transplantation for myelofibrosis in 2012Br J Haematol2012157441342522463701
   PubMed Web of Science ®Google Scholar
• MascarenhasJRuxolitinib Prior to Transplant in Patients With Myelofibrosis Available from: http://clinicaltrials.gov/show/NCT01790295Accessed July 29, 2013
   Google Scholar
• Martínez-TrillosAGayaAMaffioliMEfficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patientsAnn Hematol201089121233123720567824
   PubMed Web of Science ®Google Scholar
• FaoroLNTefferiAMesaRALong-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasiaEur J Haematol200574211712015654901
   PubMed Web of Science ®Google Scholar
• IanottoJCKiladjianJJDemoryJLPEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)Br J Haematol2009146222322519545286
   PubMed Web of Science ®Google Scholar
• MesaRAHow I treat symptomatic splenomegaly in patients with myelofibrosisBlood2009113225394540019332765
   PubMed Web of Science ®Google Scholar
• ElliottMATefferiASplenic irradiation in myelofibrosis with myeloid metaplasia: a reviewBlood Rev199913316317010527268
   PubMed Web of Science ®Google Scholar
• CervantesFAlvarez-LarránAHernández-BoludaJCSuredaATorrebadellMMontserratEErythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literatureBr J Haematol2004127439940315521916
   PubMed Web of Science ®Google Scholar
• McMullinMFHarrisonCNNiederwieserDThe use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF)Blood (ASH Annual Meeting Abstracts)2012120212838
   Web of Science ®Google Scholar
• KennedyBJEffect of androgenic hormone in myelofibrosisJAMA196218211611914031935
   PubMed Web of Science ®Google Scholar
• CervantesFAlvarez-LarránADomingoAArellano-RodrigoEMontserratEEfficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patientsBr J Haematol2005129677177515953003
   PubMed Web of Science ®Google Scholar
• ThapaliyaPTefferiAPardananiAInternational working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimensAm J Hematol2011861969821132732
   PubMed Web of Science ®Google Scholar
• WeinkoveRReillyJTMcMullinMFCurtinNJRadiaDHarrisonCNLow-dose thalidomide in myelofibrosisHaematologica20089371100110118508796
   PubMed Web of Science ®Google Scholar
• TefferiALashoTLMesaRAPardananiAKetterlingRPHansonCALenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissionsLeukemia20072181827182817460705
   PubMed Web of Science ®Google Scholar
• ShastriACortesJEJabbourEJA phase II study of low-dose pomalidomide (0.5 mg/day) and prednisone combination therapy in patients with myelofibrosis and significant anaemiaBlood (ASH Annual Meeting Abstracts)2012120211728
   Web of Science ®Google Scholar
• BegnaKHMesaRAPardananiAA phase-2 trial of low-dose pomalidomide in myelofibrosisLeukemia201125230130421052089
   PubMed Web of Science ®Google Scholar
• MesaRAPardananiADHusseinKPhase 1/-2 study of pomalidomide in myelofibrosisAm J Hematol201085212913020052748
   PubMed Web of Science ®Google Scholar
• TefferiAVerstovsekSBarosiGPomalidomide is active in the treatment of anaemia associated with myelofibrosisJ Clin Oncol200927274563456919652059
   PubMed Web of Science ®Google Scholar
• TefferiAPrimary myelofibrosis: 2012 update on diagnosis, risk stratification, and managementAm J Hematol201186121017102622086865
   PubMed Web of Science ®Google Scholar
• GuglielmelliPBarosiGRambaldiASafety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosisBlood201111882069207621725052
   PubMed Web of Science ®Google Scholar
• VannucchiAMBoganiCBartalucciNThe mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasmsBlood (ASH Annual Meeting Abstracts)2009114222914
   Web of Science ®Google Scholar
• VannucchiAMGuglielmelliPLupoLA phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final resultsBlood (ASH Annual Meeting Abstracts)201011621314
   Google Scholar
• MarksPAXuWSHistone deacetylase inhibitors: potential in cancer therapyJ Cell Biochem2009107460060819459166
   PubMed Web of Science ®Google Scholar
• BoldenJEPeartMJJohnstoneRWAnticancer activities of histone deacetylase inhibitorsNat Rev Drug Discov20065976978416955068
   PubMed Web of Science ®Google Scholar
• MascarenhasJLuMLiTA phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)Br J Haematol20131611687523330839
   PubMed Web of Science ®Google Scholar
• DeAngeloDJTefferiAFiskusWA phase II trial of panobinostat, an orally available deacetylase inhibitor, in patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosisBlood (ASH Annual Meeting Abstracts)201011621630
   Web of Science ®Google Scholar
• HarrisonCVerstovsekSMcMullinMFMesaRJanus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Br J Haematol2012157442643722463737
   PubMed Web of Science ®Google Scholar
• HarrisonCNKiladjianJPassamontiFA phase 1b dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosisHaematologica201297Suppl 1146 [abstract 0364]
   Google Scholar
• Jakavi (ruxolitinib) [product monograph]Dorval, QCNovartis Pharmaceuticals Canada, Inc2012
   Google Scholar
• MascarenhasJHoffmanRA comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosisBlood2013121244832483723570800
   PubMed Web of Science ®Google Scholar